Member Info for B2HS2L

Waiting for response to 11:38 post (if Perez get one).

"But I'm off to ODX at least some signs of life there"

Must have looked at Parkez's 09:08 post - realised he had shot his mouth off, & decided a quick exit was in order.

Smells fresher already..

mandy.cowling@novacyt.com - Corporate & Investor Relations Manager at Novacyt Group.

Parkez - I'd be very interested if this mailbox is "undergoing maintenance and can't accept messages now."

Morning Star confirms the holding we are seeing here, ie Jean-Pierre Crinelli = 91,090 share sale unaccounted for.
Perhaps there was an event where many directors sold, so calls into question the holding of other directors.

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/NCYT/14553641.html

RE: Mobile testing:

Amazon jungle anyone?

https://www.youtube.com/watch?v=M9F1ZWxlehc

q16 instrument combined with the speed of dPCR is a very good combination.

Thanks Danny, - you don't have enough posts to enable the posting of links.
Unsure what the limit is.

Thanks Danny, - Thats
1 sante
2 French Government.

Haven't heard of Sante before, are they global?

Yes Ponkey, he is saying that due to an administrative error, you cannot get reimbursed by the Social Security for our test.

So that means that there is probably other RT-qPCR tests that are reimbursable.

Danny could I ask you please to advise on this, or does it depend on which region you live in or some other criteria ?

Hi Ponkey, - Anybody,
Who has sold to the French government in large amounts then please?
I've spent a long time catching up with discussions on this board recently, and haven't seen anything about the subject discussed recently.
Thanks .

With respect to the export of 40,000 Primerdesign test kits to Egypt:

Newspapers tell us that there is still a shortage of PPE in UK hospitals and care homes.

It would not surprise me to see further test kits exported to Egypt, in exchange for the manufacture of more PPE for UK.

I don't see why a one-off export of 40,000 kits would be the end of the agreement, especially if we see a second spike in C19 diagnosis in both countries.

I was unhappy that I only had until 9 pm last night to find funds to invest, so didn't bother.
Instead I decided to wait until 10th June and after, as I judged that my be the
optimum time to pick up shares. I'd have time to find more funds as well.
Take care of your health guys, what ever you have decided.

Fumbs - Many thanks for clarification :)

The company tried to raise £12M last night and ended up raising £14M+

Does anyone have an opinion if this amount of cash was raised in addition to the MidCap loan,
or was it to pay-off the $2M outstanding loan and loose MidCap?

I would like to know if we have raised money partly to pay off a loan, or to start paying the repayments.

For Info: $20M was required in June last year, when the company had £8M (I believe) working capital.

Old B,
I did sense that posters were gving the BoD an easy time, and expecting them to come up with the goods,
because of the potential available.

I tried hard to change that attitude, to make sure posters saw the BoD were not without fault
and making one or two poor decisions.

They did not communicate enough.

As I've said we don't know what they will do about the loan, draw down tranche 2 or repay $2Mil.

Lets hope the sp bounces tomorrow.

This is the loan size and nature of the original Mid-Cap loan in June 2019, when they had a lot more working capital:

Leeds, 4 June 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix", or the "Company" and together with its subsidiaries, the "Group"), the regenerative medical devices company, announces that it has and certain of its subsidiaries have unconditionally entered into agreements with MidCap Financial Trust ("MidCap Financial") to access a revolving credit facility and a term loan credit facility (the "Facilities") of up to $20 million. Funding of $10.5 million is initially available to the Group, of which it plans to draw down an initial $7.5 million immediately.

++++

Concerned that they have not said what will happen to the outstanding loan as adjusted in Nov 2019.

Are they going to draw down tranche 2, or pay off the $2Mil to show MidCap the door.

PL75,
Thanks for your correction, I was writing about BooHoo and meant Medusa.
From todays Gaurdian article.
"Alistair Smith, Avacta’s chief executive, said the price of the test would probably be similar to a commercial HIV test, which cost about $30 (£25)"
I think it is fair to assume BooHoo and Medusa will do whatever is cheapest / most expedient.
$30 / (£25) seems reasonable (with delivery).

Stu, - Thats the angle I was looking at.
From the RNS:
"The manufacturing agreement follows collaboration between the R&D teams of both companies to develop a new product using one of the Group's proprietary technology platforms to address orthopaedic soft tissue repairs. Processing for the product has begun, and initial orders have been received. Over the next two years, it is expected that the product will make a material contribution to the Group's top line revenue growth."

This 'white label'arrangement was agreed long ago, and so was the finance for it.

Since we are so skint, did the partner underwrite our R&D costs, - thus already invested, and if so, should an RNS have been generated.

I think BooHoo.com wanted the job of distributing the POC device because it forces them to set up the global distribution network required.

If I worked for BooHoo, I would see the global network developing and maturing very rapidly in response to investment.
The agreement with Avacta repays the investment, and BooHoo gets to distribute its wares to new destinations at a substantial discount.

So Avacta can be sure that BooHoo is incentivised to set the network up ASAP.

21 May 06:00

https://www.theguardian.com/business/2020/may/21/boohoo-founders-team-up-with-biotech-firm-for-covid-19-home-test-kit-uk-july

Takeaways from this article:
1 Avacta based in Wetherby not Cambridge

2 The test kit is still in development and needs to be approved by regulators, but the company expects it to be available in the UK in July. Regulatory approval will also be sought in the rest of Europe as well as in the US.

3 Alistair Smith, Avacta’s chief executive, said the price of the test would probably be similar to a commercial HIV test, which cost about $30 (£25), but would be lower if health organisations or businesses bought it in bulk. The company said it had had inquiries from firms that wanted to test staff to ensure they are healthy before they return to work.